Literature DB >> 30852149

Current treatment of behavioral and cognitive symptoms of Parkinson's disease.

Irena Rektorova1.   

Abstract

Cognitive and behavioral symptoms are common in Parkinson's disease, may occur even in the prodromal stages of the disease, worsen with disease progression, and surpass motor symptoms as the major factors affecting patient quality of life and caregiver burden. The symptoms may be caused by the disease pathology or they may represent adverse effects of treatment, or both etiological factors may contribute. Although many of these symptoms are related to dopaminergic dysfunction or dopaminergic medication, other neurotransmitters are involved as well. Behavioral symptoms including impulse control disorders, apathy, psychosis, as well as mild cognitive impairment and dementia are reviewed with a special focus on current treatment approaches.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Apathy; Behavioral; Cognitive; Dementia; Dopaminergic; Impulse control disorders; Mild cognitive impairment; Parkinson's disease; Psychosis; treatment

Mesh:

Year:  2019        PMID: 30852149     DOI: 10.1016/j.parkreldis.2019.02.042

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  8 in total

1.  Pharmacologic Approaches for the Management of Apathy in Neurodegenerative Disorders.

Authors:  Anamaria Bogdan; Valeria Manera; Alexandra Koenig; Renaud David
Journal:  Front Pharmacol       Date:  2020-01-23       Impact factor: 5.810

2.  The path linking disease severity and cognitive function with quality of life in Parkinson's disease: the mediating effect of activities of daily living and depression.

Authors:  Yao He; Yuling Tian; Hongjuan Han; Jing Cui; Xiaoyan Ge; Yao Qin; Yanhong Luo; Wenlin Bai; Hongmei Yu
Journal:  Health Qual Life Outcomes       Date:  2021-03-17       Impact factor: 3.186

Review 3.  Venoms as an adjunctive therapy for Parkinson's disease: where are we now and where are we going?

Authors:  Parisa Gazerani
Journal:  Future Sci OA       Date:  2020-11-30

4.  Impact of Supporting People with Advanced Parkinson's Disease on Carer's Quality of Life and Burden.

Authors:  Nicola Modugno; Angelo Antonini; Alessandro Tessitore; Pietro Marano; Francesco Ernesto Pontieri; Nicola Tambasco; Margherita Canesi; Giovanni Fabbrini; Mariachiara Sensi; Rocco Quatrale; Paolo Solla; Giovanni Defazio; Gabriella Melzi; Giuliana Gualberti; Leonardo Lopiano
Journal:  Neuropsychiatr Dis Treat       Date:  2020-12-02       Impact factor: 2.570

Review 5.  Multisite non-invasive brain stimulation in Parkinson's disease: A scoping review.

Authors:  Camila Beatriz da Silva Machado; Letícia Maria da Silva; Alessandra Feitosa Gonçalves; Palloma Rodrigues de Andrade; Cristina Katya Torres Teixeira Mendes; Thais Josy Castro Freire de Assis; Clécio de Oliveira Godeiro Júnior; Suellen Marinho Andrade
Journal:  NeuroRehabilitation       Date:  2021       Impact factor: 2.138

6.  Efficacy of Cognitive Behavioral Therapy on Mood Disorders, Sleep, Fatigue, and Quality of Life in Parkinson's Disease: A Systematic Review and Meta-Analysis.

Authors:  Fangyi Luo; Mengfei Ye; Tingting Lv; Baiqi Hu; Jiaqi Chen; Junwei Yan; Anzhe Wang; Feng Chen; Ziyi He; Zhinan Ding; Jian Zhang; Chao Qian; Zheng Liu
Journal:  Front Psychiatry       Date:  2021-12-13       Impact factor: 4.157

7.  Dl-3-n-Butylphthalide Alleviates Behavioral and Cognitive Symptoms Via Modulating Mitochondrial Dynamics in the A53T-α-Synuclein Mouse Model of Parkinson's Disease.

Authors:  Huiying Li; Hongquan Wang; Ling Zhang; Manshi Wang; Yanfeng Li
Journal:  Front Neurosci       Date:  2021-05-28       Impact factor: 4.677

8.  A Systematic Review of Neuromodulation Treatment Effects on Suicidality.

Authors:  Mehmet Utku Kucuker; Ammar G Almorsy; Ayse Irem Sonmez; Anna N Ligezka; Deniz Doruk Camsari; Charles P Lewis; Paul E Croarkin
Journal:  Front Hum Neurosci       Date:  2021-06-25       Impact factor: 3.169

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.